快速现场评估对甲状腺结节细针穿刺质量及诊断价值的影响
本回顾性队列研究评估了快速现场评估(ROSE)对甲状腺细针穿刺(FNA)标本质量及诊断价值的影响。共纳入5030例甲状腺FNA,其中ROSE组1304例(25.9%),非ROSE组3726例(74.1%)。结果显示ROSE可降低Bethesda I和III类比例,提高Bethesda II和VI类诊断率,并改善诊断准确性(AUC ROSE 0.895 vs 非ROSE 0.811,p=0.004)。作者建议考虑将ROSE作为甲状腺FNA的标准诊疗。
要点
- ROSE组Bethesda I和III类比例(4.3%)低于非ROSE组(39.9%),p<0.001。
- ROSE组Bethesda II和VI类诊断率91.6%,高于非ROSE组56.6%,p<0.001。
- ROSE组诊断准确性AUC 0.895优于非ROSE组0.811,p=0.004。
核心结论
- ROSE通过定量和定性改善FNA标本,显著提高了诊断准确性。
- 作者建议考虑将ROSE作为甲状腺FNA的标准诊疗。
研究设计与样本
- 回顾性队列研究,比较接受ROSE与未接受ROSE的甲状腺FNA标本的Bethesda分类和标本质量。
- 共评估5030例甲状腺FNA,ROSE组1304例(25.9%),非ROSE组3726例(74.1%)。
主要发现
- ROSE组Bethesda I和III类比例4.3%(56/1304),非ROSE组39.9%(1487/3726),p<0.001。
- ROSE组Bethesda II和VI类诊断率91.6%(1194/1270),非ROSE组56.6%(1999/3530),p<0.001。
- 诊断准确性AUC:ROSE组0.895,非ROSE组0.811,p=0.004。
- Bethesda III和V类中细胞稀疏的标本比例:ROSE组0.1%(1/1304),非ROSE组1.2%(45/3726),p<0.001。
- 总体伪影率:ROSE组0.3%(4/1304),非ROSE组2.5%(92/3726),p<0.001。
临床怎么用
- 作者建议考虑将ROSE作为甲状腺FNA的标准诊疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Ultrasound-guided fine-needle aspiration (FNA) is the preferred method to evaluate the dignity of thyroid nodules. Nevertheless, the often-reported high nondiagnostic rate burdens affected patients and the health care system. Rapid on-site evaluation (ROSE) constitutes an addition to the thyroid FNA procedure, with various studies showing its beneficial effect on the Bethesda I nondiagnostic rate. We aimed to assess whether ROSE may reduce the rate of Bethesda categories III and V. Additionally, we examined the influence of ROSE on specimen quality. Methods: We performed a retrospective cohort study, comparing Bethesda categorization and specimen quality in specimens subject to ROSE compared with those not subject to ROSE. We also evaluated aspects of specimen quality that differed according to the use of ROSE. We subcategorized Bethesda I into insufficient cellularity or artifacts, and Bethesda categories III and V into cellular without artifacts, sparsely cellular, or artifacts. Results: We evaluated 5030 thyroid FNAs. ROSE was performed in 1304 (25.9%) cases, and ROSE was not utilized for 3726 (74.1%) specimens. The rate of Bethesda I nondiagnostic and Bethesda III categories was reduced in specimens subject to ROSE (4.3%, 56/1304) compared with non-ROSE (39.9%, 1487/3726, p < 0.001). The rate of both benign Bethesda II and malignant Bethesda VI diagnoses was 91.6% (1194/1270) in ROSE specimens compared with 56.6% (1999/3530) in non-ROSE (p < 0.001). This was reflected by a significant improvement in diagnostic accuracy with ROSE (areas under the curve [AUC]non-ROSE = 0.811, AUCROSE = 0.895, p = 0.004). The overall rate of specimens flawed by sparse cellularity in Bethesda categories III and V was 0.1% (1/1304) in ROSE specimens compared with 1.2% (45/3726) in non-ROSE (p < 0.001). The overall artifact rate was 0.3% (4/1304) for ROSE specimens and 2.5% (92/3726) for non-ROSE (p < 0.001). Conclusions: ROSE significantly increased diagnostic accuracy by improving FNA specimens quantitatively and qualitatively. We suggest considering ROSE as standard of care for thyroid FNAs.
引用
- Muri R, Trippel M, Borner U, et al. The Impact of Rapid On-Site Evaluation on the Quality and Diagnostic Value of Thyroid Nodule Fine-Needle Aspirations. Thyroid. 2022. PMID: 35236111. doi:10.1089/thy.2021.0551
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。